Siremadlin — Investigational Agent
Other · Phase 1/2 · Novartis
Mechanism of Action
Oral small-molecule MDM2 inhibitor that blocks the MDM2-p53 interaction, stabilizing and reactivating wild-type p53 to drive apoptosis and cell-cycle arrest in TP53-wildtype myeloid malignancies.
Investigational Indications
- Acute myeloid leukemia
- Myelodysplastic syndromes